Your session is about to expire
← Back to Search
Brain Biomarker on Inflammation Response for Schizophrenia (LPS Trial)
LPS Trial Summary
This trial will study whether lipopolysaccharide (LPS) can trigger schizophrenia symptoms in patients with a schizophrenia spectrum disorder. The trial will have two comparison groups: an age- and sex-matched healthy control group that will be exposed to the same LPS, and an age- and sex-matched sample of patients with schizophrenia who will receive a placebo.
- Schizophrenia
LPS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 4 trial • 16 Patients • NCT02875028LPS Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have a history of fainting multiple times without a known cause.You have another health condition called rheumatoid arthritis that causes inflammation.You currently have an infection or have had a flu shot or similar vaccine in the last 4 weeks.You are currently taking non-steroidal anti-inflammatory drugs or medications that affect your immune system on a regular basis.You have been diagnosed with a substance use disorder (except for nicotine and marijuana) within the past 6 months.You have attempted suicide before, think about it often, or currently have thoughts of hurting yourself, as determined by a test called the Columbia Suicide Severity Rating Scale (C-SSRS).You are pregnant, planning to become pregnant, or currently breastfeeding.Your blood pressure is too low (below 90/60) or too high (above 150/100), your pulse is too slow (below 55) or too fast (above 100 beats per minute), or your temperature is higher than 99.5°F.You have a history of brain disorders like seizures, brain tumors, or head injuries that have caused significant problems with thinking and memory.
- Group 1: LPS-Patient
- Group 2: LPS-Healthy
- Group 3: Placebo-Patient
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it possible to join this research project?
"This research is accepting 75 individuals with schizophrenia between the ages of 15 and 55. To qualify, applicants must attain a score of 10 or higher on an ESC test, be taking antipsychotic medication which has remained stable for the last four weeks, have a BMI no greater than 35, and fall within the specified age range."
Has the Food and Drug Administration given their seal of approval to LPS?
"LPS's safety is supported by minimal clinical data, thus receiving a score of 1."
Are there any slots available for this experiment?
"Per information on clinicaltrials.gov, this research is not currently enrolling participants. The trial was initially uploaded on January 1st 2025 and last updated October 10th 2022. Although no longer recruiting people to join the study, there are 685 other medical studies actively looking for volunteers right now."
Are individuals 35 and older being included in this trial?
"According to the criteria stipulated on clinicaltrials.gov, suitable candidates for this trial should range from 15-55 years old. For those younger than 15 and older than 65, 72 and 430 studies are available respectively."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger